Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia.

ABSTRACT:

Background

Chronic myelomonocytic leukemia (CMML) is an aggressive hematopoietic malignancy that arises from hematopoietic stem and progenitor cells (HSPCs). Patients with CMML are frequently treated with epigenetic therapeutic approaches, in particular the hypomethylating agents (HMAs), azacitidine (Aza) and decitabine (Dec). Although HMAs are believed to mediate their efficacy via re-expression of hypermethylated tumor suppressors, knowledge about relevant HMA targets is scarce. As silencing of tumor-suppressive micro-RNAs (miRs) by promoter hypermethylation is a crucial step in malignant transformation, we asked for a role of miRs in HMA efficacy in CMML.

Results

Initially, we performed genome-wide miR-expression profiling in a Kras^G12D-induced CMML mouse model

SUBMITTER: Berg JL 

PROVIDER: S-EPMC7789782 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature